Prohibits the sale of medical adhesives and bandages containing perfluoroalkyl and polyfluoroalkyl substances; provides penalties for violations.
Summary
A01430 would amend the Environmental Conservation Law to prohibit the sale in New York of medical adhesives and bandages that contain PFAS, either as intentionally added chemicals or above a threshold level to be set by the Department of Environmental Conservation in regulation. The bill defines the covered products broadly as medical-purpose adhesive strips or bandages used to cover wounds, support injured body parts, or secure objects to the skin, while excluding medical devices under exclusive federal FDA jurisdiction.
The bill also creates a compliance framework for manufacturers and sellers. After December 31, 2026, sellers would be protected from liability if they relied in good faith on a manufacturer’s written certificate of compliance, but manufacturers could be penalized for issuing false certificates. The measure authorizes civil penalties and injunctive relief for violations, with higher penalties for repeat violations, and directs the state to adopt any necessary implementing regulations immediately.
Impact
If enacted, the bill would add a new PFAS restriction to New York’s environmental product standards and expand the state’s existing chemical-regulation framework to include certain medical adhesive products and bandages. It would affect manufacturers, importers, distributors, and retailers of wound-care and first-aid products, and would require the Department of Environmental Conservation to establish regulatory thresholds for PFAS content. The bill also amends the civil penalty provisions of the Environmental Conservation Law to enforce the new prohibition.
Sentiment
The available voting history suggests generally favorable support for the bill, with the Assembly Environmental Conservation Committee voting 24-6 to refer it onward. That vote indicates substantial support for restricting PFAS in consumer and medical products, consistent with broader environmental and public-health concerns about “forever chemicals.” No committee transcript is available here, so the record does not show detailed floor or committee debate beyond the vote itself.
Contention
The main points of potential contention are the scope of the PFAS ban and its interaction with federally regulated medical devices. Manufacturers and sellers may be concerned about compliance costs, product reformulation, supply-chain certification, and the need to meet a future regulatory threshold that is not specified in the bill text. Another likely issue is whether the state should regulate products used for medical purposes at all, especially where federal FDA jurisdiction may overlap. Supporters are likely to emphasize environmental and health protection, while critics may focus on implementation uncertainty and the burden on the medical supply chain.
Same As
Prohibits the sale of medical adhesives and bandages containing perfluoroalkyl and polyfluoroalkyl substances; provides penalties for violations.